Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study
Yves Dauvilliers(Inserm), Richard Bogan(University of South Carolina), Anne Marie Morse(Geisinger Medical Center), Michael J. Thorpy(Albert Einstein College of Medicine), Nancy Foldvary‐Schaefer(Cleveland Clinic), Amanda Sterkel(Jazz Pharmaceuticals (United States)), Franck Skobieranda(Ionis Pharmaceuticals (United States)), Isabelle Arnulf(Centre National de la Recherche Scientifique), Emmanuel Mignot(Stanford University), Dan Chen(Yunnan University), Patricia Chandler(Jazz Pharmaceuticals (United States)), Karel Šonka(Charles University), Jed Black(Jazz Pharmaceuticals (United States)), Rupa Parvataneni(UCSF Helen Diller Family Comprehensive Cancer Center)
Cited by 67
Related Papers
National Sleep Foundation's sleep quality recommendations: first report
|Sleep Health|2016|1.3k
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
|Brain|2019|1.1k
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis
|The Lancet|2016|1k
Narcolepsy with cataplexy
|The Lancet|2007|716
Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment
|Nature Reviews Neurology|2019|634